# Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043)

> **NCT05115838** · PHASE2 · WITHDRAWN · sponsor: **Merck Sharp & Dohme LLC**

## Conditions studied

- Human Immunodeficiency Virus
- HIV

## Interventions

- **DRUG:** Islatravir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05115838
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-01-04
- **Primary completion:** 2025-10-02
- **Final completion:** 2025-10-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business Reasons
- **Last updated:** 2023-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05115838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05115838, "Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05115838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*